← All trials
NCT05248672
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 2, 2022
- Primary completion
- May 25, 2022
- Completion date
- May 25, 2022
- First posted
- Feb 21, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 35
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cognition TherapeuticsLead sponsor
- Cognition TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.